These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36559326)

  • 41. Cost-Utility Analysis of Pharmacogenetic Testing Based on CYP2C19 or CYP2D6 in Major Depressive Disorder: Assessing the Drivers of Different Cost-Effectiveness Levels from an Italian Societal Perspective.
    Carta A; Del Zompo M; Meloni A; Mola F; Paribello P; Pinna F; Pinna M; Pisanu C; Manchia M; Squassina A; Carpiniello B; Conversano C
    Clin Drug Investig; 2022 Sep; 42(9):733-746. PubMed ID: 35930170
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects.
    Darwish M; Kirby M; Robertson P; Hellriegel ET
    Clin Pharmacokinet; 2008; 47(1):61-74. PubMed ID: 18076219
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
    Walzer M; Bekersky I; Blum RA; Tolbert D
    Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Physiologically-based pharmacokinetic modelling of a CYP2C19 substrate, BMS-823778, utilizing pharmacogenetic data.
    Gong J; Iacono L; Iyer RA; Humphreys WG; Zheng M
    Br J Clin Pharmacol; 2018 Jun; 84(6):1335-1345. PubMed ID: 29469197
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Physiologically based pharmacokinetic modeling to predict exposures in healthy Japanese subjects with different CYP2C19 phenotypes: Esomeprazole case study
.
    Higashimori M; Shimada H; Ichikawa K; Zhou D
    Int J Clin Pharmacol Ther; 2020 Jan; 58(1):29-36. PubMed ID: 31657713
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Therapeutic Drug Monitoring and Pharmacogenetic Testing as Guides to Psychotropic Drug Dose Adjustment: An Observational Study.
    Cuvelier E; Khazri H; Lecluse C; Hennart B; Amad A; Roche J; Tod M; Vaiva G; Cottencin O; Odou P; Allorge D; Décaudin B; Simon N
    Pharmaceuticals (Basel); 2023 Dec; 17(1):. PubMed ID: 38256855
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Physiologically based pharmacokinetic modeling of brivaracetam and its interactions with rifampin based on CYP2C19 phenotypes.
    Yang H; Yang L; Zhong X; Jiang X; Zheng L; Wang L
    Eur J Pharm Sci; 2022 Oct; 177():106258. PubMed ID: 35840101
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Developmental pharmacogenetics of CYP2C19 in neonates and young infants: omeprazole as a probe drug.
    Zhao W; Leroux S; Biran V; Jacqz-Aigrain E
    Br J Clin Pharmacol; 2018 May; 84(5):997-1005. PubMed ID: 29377228
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Optimizing clopidogrel dose response: a new clinical algorithm comprising CYP2C19 pharmacogenetics and drug interactions.
    Saab YB; Zeenny R; Ramadan WH
    Ther Clin Risk Manag; 2015; 11():1421-7. PubMed ID: 26445541
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [State of the art of pharmacogenetic diagnostics in drug therapy].
    Kirchheiner J; Seeringer A; Brockmöller J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Oct; 49(10):995-1003. PubMed ID: 17013776
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.
    Ekhart C; Doodeman VD; Rodenhuis S; Smits PH; Beijnen JH; Huitema AD
    Pharmacogenet Genomics; 2008 Jun; 18(6):515-23. PubMed ID: 18496131
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy.
    Steimer W; Zöpf K; von Amelunxen S; Pfeiffer H; Bachofer J; Popp J; Messner B; Kissling W; Leucht S
    Clin Chem; 2005 Feb; 51(2):376-85. PubMed ID: 15590749
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Genetic polymorphism of CYP2C19 and subcortical variability in the human adult brain.
    Stingl JC; Scholl C; Bosch JE; Viviani R
    Transl Psychiatry; 2021 Sep; 11(1):467. PubMed ID: 34497262
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cytochrome P450 in Pharmacogenetics: An Update.
    Tornio A; Backman JT
    Adv Pharmacol; 2018; 83():3-32. PubMed ID: 29801580
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Physiologically based pharmacokinetic modeling for sequential metabolism: effect of CYP2C19 genetic polymorphism on clopidogrel and clopidogrel active metabolite pharmacokinetics.
    Djebli N; Fabre D; Boulenc X; Fabre G; Sultan E; Hurbin F
    Drug Metab Dispos; 2015 Apr; 43(4):510-22. PubMed ID: 25609219
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CYP2C19 Loss-of-function Polymorphisms are Associated with Reduced Risk of Sulfonylurea Treatment Failure in Chinese Patients with Type 2 Diabetes.
    Wang K; Yang A; Shi M; Tam CCH; Lau ESH; Fan B; Lim CKP; Lee HM; Kong APS; Luk AOY; Tomlinson B; Ma RCW; Chan JCN; Chow E
    Clin Pharmacol Ther; 2022 Feb; 111(2):461-469. PubMed ID: 34656068
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Systematic evaluation of commercial pharmacogenetic testing in psychiatry: a focus on CYP2D6 and CYP2C19 allele coverage and results reporting.
    Bousman CA; Jaksa P; Pantelis C
    Pharmacogenet Genomics; 2017 Nov; 27(11):387-393. PubMed ID: 28777243
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies.
    Fabbri C; Tansey KE; Perlis RH; Hauser J; Henigsberg N; Maier W; Mors O; Placentino A; Rietschel M; Souery D; Breen G; Curtis C; Lee SH; Newhouse S; Patel H; O'Donovan M; Lewis G; Jenkins G; Weinshilboum RM; Farmer A; Aitchison KJ; Craig I; McGuffin P; Schruers K; Biernacka JM; Uher R; Lewis CM
    Eur Neuropsychopharmacol; 2018 Aug; 28(8):945-954. PubMed ID: 30135031
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam.
    Veiga MI; Asimus S; Ferreira PE; Martins JP; Cavaco I; Ribeiro V; Hai TN; Petzold MG; Björkman A; Ashton M; Gil JP
    Eur J Clin Pharmacol; 2009 Apr; 65(4):355-63. PubMed ID: 18979093
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world.
    Xie HG; Stein CM; Kim RB; Wilkinson GR; Flockhart DA; Wood AJ
    Pharmacogenetics; 1999 Oct; 9(5):539-49. PubMed ID: 10591534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.